ATE477242T1 - Chinoline als allosterische enhancer von gaba-b- rezeptoren - Google Patents

Chinoline als allosterische enhancer von gaba-b- rezeptoren

Info

Publication number
ATE477242T1
ATE477242T1 AT05800636T AT05800636T ATE477242T1 AT E477242 T1 ATE477242 T1 AT E477242T1 AT 05800636 T AT05800636 T AT 05800636T AT 05800636 T AT05800636 T AT 05800636T AT E477242 T1 ATE477242 T1 AT E477242T1
Authority
AT
Austria
Prior art keywords
quinolines
gaba
receptors
allosteric enhancers
allosteric
Prior art date
Application number
AT05800636T
Other languages
English (en)
Inventor
Parichehr Malherbe
Raffaello Masciadri
Roger Norcross
Hasane Ratni
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE477242T1 publication Critical patent/ATE477242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AT05800636T 2004-11-01 2005-10-25 Chinoline als allosterische enhancer von gaba-b- rezeptoren ATE477242T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105429 2004-11-01
PCT/EP2005/011403 WO2006048146A1 (en) 2004-11-01 2005-10-25 Quinoline as allosteric enhancers of the gaba-b receptors

Publications (1)

Publication Number Publication Date
ATE477242T1 true ATE477242T1 (de) 2010-08-15

Family

ID=35735244

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05800636T ATE477242T1 (de) 2004-11-01 2005-10-25 Chinoline als allosterische enhancer von gaba-b- rezeptoren

Country Status (16)

Country Link
US (1) US7576217B2 (de)
EP (1) EP1809605B1 (de)
JP (1) JP2008517963A (de)
KR (1) KR100876470B1 (de)
CN (1) CN101068788A (de)
AR (1) AR051612A1 (de)
AT (1) ATE477242T1 (de)
AU (1) AU2005300822B2 (de)
BR (1) BRPI0517929A (de)
CA (1) CA2586066A1 (de)
DE (1) DE602005022908D1 (de)
ES (1) ES2348246T3 (de)
MX (1) MX2007005112A (de)
RU (1) RU2378256C2 (de)
TW (1) TW200630341A (de)
WO (1) WO2006048146A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2074123T1 (sl) 2006-10-16 2013-03-29 Bionomics Limited Nove anksiolitične spojine
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2009041904A1 (en) * 2007-09-27 2009-04-02 Astrazeneca Ab Quinoline compounds having an activity against the gabab receptor
WO2012116415A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
EP3678666B1 (de) 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Spezifischer akt3-aktivator und dessen verwendungen
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414200D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414199D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel Compounds
GB202414192D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them
JPH0853419A (ja) * 1994-06-07 1996-02-27 Takeda Chem Ind Ltd キノリン誘導体およびそれらを含んでなる医薬
MXPA01011173A (es) * 1999-05-06 2002-04-24 Neurogen Corp 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba.
JP2002371078A (ja) * 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds
GB0226462D0 (en) * 2002-11-13 2002-12-18 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DE602005022908D1 (de) 2010-09-23
EP1809605B1 (de) 2010-08-11
AU2005300822A1 (en) 2006-05-11
RU2378256C2 (ru) 2010-01-10
KR20070085594A (ko) 2007-08-27
RU2007115639A (ru) 2008-12-10
MX2007005112A (es) 2007-06-26
JP2008517963A (ja) 2008-05-29
KR100876470B1 (ko) 2008-12-31
US20060094754A1 (en) 2006-05-04
WO2006048146A1 (en) 2006-05-11
US7576217B2 (en) 2009-08-18
CA2586066A1 (en) 2006-05-11
AR051612A1 (es) 2007-01-24
AU2005300822B2 (en) 2010-12-02
ES2348246T3 (es) 2010-12-01
TW200630341A (en) 2006-09-01
CN101068788A (zh) 2007-11-07
BRPI0517929A (pt) 2008-10-21
EP1809605A1 (de) 2007-07-25

Similar Documents

Publication Publication Date Title
DE60320529D1 (de) Chinolinderivate als npy antagonisten
IS8304A (is) Kínólín- og kínasólínafleiður með sækni í viðtaka af gerð 5HT1
DE602004027998D1 (de) Kondensierte n-heterozyclische verbindung und ihre verwendung als crf-rezeptor antagonist
DE602005016890D1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE498613T1 (de) Chinazolinonderivate als parp-hemmer
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
DE502005011241D1 (de) Indazolderivate als inhibitoren der hormon-sensitiven lipase
DE602005012267D1 (de) N von geräten
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DE602005012292D1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DK1802579T3 (da) Derivater af 3-arylaminopyridin
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
DE602005006744D1 (de) Chinolinderivate zur verwendung als inhibitoren von mycobakterien
DE602005025363D1 (de) Substituierte amide als inhibitoren der beta-sekretase
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DE602006010870D1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
ATE412652T1 (de) Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
DE602005002251D1 (de) Pyridazinonharnstoffe als antagonisten von a4-integrinen
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809605

Country of ref document: EP